<DOC>
	<DOCNO>NCT00492388</DOCNO>
	<brief_summary>To assess safety efficacy PMI-150 ( Intranasal Ketamine ) analgesic treatment breakthrough pain cancer patient .</brief_summary>
	<brief_title>Safety Efficacy PMI-150 ( Intranasal Ketamine ) Treatment Breakthrough Pain Cancer Patients</brief_title>
	<detailed_description>The primary objective evaluate safety efficacy follow administration intranasal ketamine provide pain relief compare placebo .</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>least 18 year age Patients require aroundtheclock opioids pain due cancer history experience episode breakthrough pain 18 year noncancer pain allergy ketamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>breakthrough</keyword>
	<keyword>pain</keyword>
	<keyword>cancer</keyword>
</DOC>